EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines

Kara Braunreiter, Amber Kempton, Maria Katherine Mejia-Guerra, Andrew Murray, Stephen Baine, Kaitlin Adegboye, Alex Haile, Suruchi Jai Kumar Ahuja, Alessandra Fedoce, Chang Liu, Peter Burch, Ami Meda Kabadi iD

Disease Models & Mechanisms · 01.10.2025 · 18 (10)

DOI: 10.1242/dmm.052182 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 17.10.2025. Verfasst von Kara Braunreiter und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sarepta Therapeutics Inc., Cambridge, MA 02142, USA. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Genetic Therapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sarepta Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Duchenne muscular dystrophy (DMD) is a rare, progressive neuromuscular disease resulting from DMD variants, leading to loss of functional dystrophin. To evaluate human-targeted genetic medicines for functional dystrophin restoration, humanized genetic models containing the full human locus are required. This study characterized the hDMDΔ52/mdx mouse model previously reported by Pickar-Oliver and colleagues. Genomic characterization confirmed complete DMD duplication with identical exon 52 deletion junctions on both copies. Histological analysis showed increased diaphragm fibrosis and skeletal muscle central nuclei in hDMDΔ52/mdx mice versus hDMD/mdx controls. hDMDΔ52/mdx mice demonstrated reduced tibialis anterior specific force, decreased skeletal muscle fiber diameter, decreased resistance to eccentric contraction-induced damage and cardiac defects. Multiple serum biomarkers of disease were identified. Using a CRISPR/Cas9 gene-editing strategy to restore human functional dystrophin protein expression, detectable dystrophin expression in the heart and skeletal muscle and increased resistance to injury in the tibialis anterior muscle were observed. In summary, hDMDΔ52/mdx mice display multiple physiological and functional deficits associated with DMD pathology, which can be restored by human-targeted therapy, confirming the suitability of this model for developing human-targeted genetic medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Muscular Dystrophy, DuchenneGenetic TherapyAnimalsDisease Models, AnimalHumansDystrophinMuscle, SkeletalMice, Inbred mdxMiceMaleDiaphragmBiomarkersGene EditingMuscle Fibers, SkeletalCRISPR-Cas SystemsMyocardiumFibrosis

Stichwörter der Autor:innen

Duchenne muscular dystrophyDystrophinGene editingMouse modelPreclinical

Substanzen

DystrophinBiomarkers

Autor:innen und Institutionen

  • Sarepta Therapeutics Inc., Cambridge, MA 02142, USA.

ORCID-Profile: Ami Meda Kabadi

Förderung

  • Sarepta Therapeutics

Zitieren

APA

Braunreiter, K., Kempton, A., Mejia-Guerra, M. K., Murray, A., Baine, S., Adegboye, K., Haile, A., Kumar Ahuja, S. J., Fedoce, A., Liu, C., Burch, P., & Kabadi, A. M. (2025). Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines. Disease Models & Mechanisms, 18(10). https://doi.org/10.1242/dmm.052182

Vancouver

Braunreiter K, Kempton A, Mejia-Guerra MK, Murray A, Baine S, Adegboye K, et al. Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines. Disease Models & Mechanisms. 2025;18(10). doi:10.1242/dmm.052182

BibTeX
@article{Braunreiter2025,
  author = {Braunreiter, Kara and Kempton, Amber and Mejia-Guerra, Maria Katherine and Murray, Andrew and Baine, Stephen and Adegboye, Kaitlin and Haile, Alex and Kumar Ahuja, Suruchi Jai and Fedoce, Alessandra and Liu, Chang and Burch, Peter and Kabadi, Ami Meda},
  title = {Characterization of a humanized mouse model of Duchenne muscular dystrophy to support the development of genetic medicines},
  journal = {Disease Models & Mechanisms},
  year = {2025},
  volume = {18},
  number = {10},
  doi = {10.1242/dmm.052182}
}
Kostenlos starten →